

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1.-120. (Cancelled)

121. (Currently Amended) A method for ~~treating a subject having cancer increasing the responsiveness to a cancer therapy comprising~~

~~administering to a subject having cancer~~ an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and ~~one or more of carboplatin, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, taxol and gemcitabine~~ in an amount effective to treat the cancer.

122. (Previously Presented) The method of claim 121, wherein the immunostimulatory oligonucleotide consists of the nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246).

123. (Previously Presented) The method of claim 121, wherein the immunostimulatory oligonucleotide is up to 100 nucleotides in length.

124. (Previously Presented) The method of claim 121, wherein the immunostimulatory oligonucleotide is 24-40 nucleotides in length.

125. (Previously Presented) The method of claim 121 or 122, wherein the immunostimulatory oligonucleotide has a nucleotide backbone which includes at least one backbone modification.

126. (Previously Presented) The method of claim 125, wherein the backbone modification is a phosphorothioate modification.

127. (Previously Presented) The method of claim 125, wherein the nucleotide backbone is entirely modified.

128. (Previously Presented) The method of claim 121 or 122, wherein the immunostimulatory oligonucleotide is administered by injection.

129. (Previously Presented) The method of claim 121 or 122, wherein the subject is a human.

130. (Previously Presented) The method of claim 121, wherein the cancer is non-small cell lung cancer.

131. (Previously Presented) The method of claim 130, wherein the subject is administered carboplatin and paclitaxel.

132. (Previously Presented) The method of claim 131, wherein the immunostimulatory oligonucleotide is 24-40 nucleotides in length.

133. (Previously Presented) The method of claim 132, wherein the immunostimulatory oligonucleotide has a nucleotide backbone which includes at least one backbone modification.

134. (Previously Presented) The method of claim 133, wherein the backbone modification is a phosphorothioate modification.

135. (Previously Presented) The method of claim 134, wherein the nucleotide backbone is entirely modified.

136. (Previously Presented) The method of claim 135, wherein the immunostimulatory oligonucleotide is administered by injection.

137. (Previously Presented) The method of claim 136, wherein the subject is a human.

138. (Previously Presented) The method of claim 137, wherein the immunostimulatory oligonucleotide consists of the nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246).

139. (New) A method for increasing the responsiveness to a cancer therapy comprising administering to a subject having cancer an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and paclitaxel in an amount effective to treat the cancer.

140. (New) A method for increasing the responsiveness to a cancer therapy comprising administering to a subject having cancer an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and doxorubicin in an amount effective to treat the cancer.

141. (New) A method for increasing the responsiveness to a cancer therapy comprising administering to a subject having cancer an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and cisplatin in an amount effective to treat the cancer.

142. (New) A method for increasing the responsiveness to a cancer therapy comprising administering to a subject having cancer an immunostimulatory oligonucleotide comprising a nucleotide sequence of

5' TCG TCG TTT TGT CGT TTT GTC GTT 3' (SEQ ID NO: 246)

and gemcitabine in an amount effective to treat the cancer.

